Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

References

• Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379(9823):1341–1351. doi:10.1016/S0140-6736(11)60968-922314182
   PubMed Web of Science ®Google Scholar
• Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15–25. doi:10.1136/thoraxjnl-2014-20673226490732
   PubMed Web of Science ®Google Scholar
• Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79(5):695–708. doi:10.1111/bcp.1254525377687
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–1196. doi:10.1016/j.chest.2016.02.64626923629
   PubMed Web of Science ®Google Scholar
• Price D, Ostrem A, Thomas M, Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review. Int J Chron Obstruct Pulmon Dis. 2017;12:141–168. doi:10.2147/COPD.S11671928115839
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922. doi:10.2147/COPD.S13048228360514
   PubMed Web of Science ®Google Scholar
• Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2:CD012066.28185242
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi:10.1056/NEJMoa140715425196117
   PubMed Web of Science ®Google Scholar
• Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to Indacaterol/Glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC29779416
   PubMed Web of Science ®Google Scholar
• Cheng SL. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:2775–2784. doi:10.2147/COPD.S17501730233168
   PubMed Web of Science ®Google Scholar
• Singh A, Liu C, Putman B, et al. Predictors of Asthma/COPD overlap in FDNY firefighters with world trade center dust exposure: a longitudinal study. Chest. 2018;154(6):1301–1310. doi:10.1016/j.chest.2018.07.00230028968
   PubMed Web of Science ®Google Scholar
• Cataldo D, Corhay JL, Derom E, et al. A Belgian survey on the diagnosis of asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2017;12:601–613. doi:10.2147/COPD.S12445928243078
   PubMed Web of Science ®Google Scholar
• Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106(7):970–979. doi:10.1016/j.rmed.2012.03.01222498110
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Wang T, Gao J, Tang H, Donohue JF. Inhaled umeclidinium in COPD patients: a review and meta-analysis. Drugs. 2016;76(3):343–361. doi:10.1007/s40265-015-0532-526755180
   PubMed Web of Science ®Google Scholar
• Rheault T, Khindri S, Vahdati-Bolouri M, Church A, Fahy WA. A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD. ERJ Open Res. 2016;2(2):00101–2015. doi:10.1183/23120541.00101-201527730198
   PubMedGoogle Scholar
• Babu KS, Morjaria JB. Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Ther Adv Chronic Dis. 2017;8(4–5):81–91. doi:10.1177/204062231770082228491268
   PubMed Web of Science ®Google Scholar
• Feldman G, Maltais F, Khindri S, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 mug compared with tiotropium 18 mug in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:719–730. doi:10.2147/COPD.S10249427103795
   PubMed Web of Science ®Google Scholar
• Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119–127. doi:10.1378/chest.11-223122241764
   PubMed Web of Science ®Google Scholar
• Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26(2):256–264. doi:10.1016/j.pupt.2012.12.00123232038
   PubMed Web of Science ®Google Scholar
• Malerba M, Radaeli A, Montuschi P, Morjaria JB. Vilanterol trifenatate for the treatment of COPD. Expert Rev Respir Med. 2016;10(7):719–731. doi:10.1080/17476348.2016.118497627143334
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Facciolo F, Rendina E, Cazzola M, Matera MG. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017;812:147–154. doi:10.1016/j.ejphar.2017.07.02628716723
   PubMed Web of Science ®Google Scholar
• Shaikh N, Johnson M, Hall DA, et al. Intracellular interactions of umeclidinium and vilanterol in human airway smooth muscle. Int J Chron Obstruct Pulmon Dis. 2017;12:1903–1913. doi:10.2147/COPD.S13442028721035
   PubMed Web of Science ®Google Scholar
• Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981–991. doi:10.1378/chest.13-157924385182
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62. 5/25mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.00123830094
   PubMed Web of Science ®Google Scholar
• Goyal N, Beerahee M, Kalberg C, Church A, Kilbride S, Mehta R. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 2014;53(7):637–648. doi:10.1007/s40262-014-0143-424756395
   PubMed Web of Science ®Google Scholar
• Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012;7(12):e50716.23284643
   PubMed Web of Science ®Google Scholar
• Hu C, Jia J, Dong K, et al. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial. PLoS One. 2015;10(3):e0121264. doi:10.1371/journal.pone.012126425816315
   PubMed Web of Science ®Google Scholar
• Feldman G, Walker RR, Brooks J, Mehta R, Crater G. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012;25(6):465–471. doi:10.1016/j.pupt.2012.08.00722955035
   PubMed Web of Science ®Google Scholar
• Mehta R, Hardes K, Brealey N, Tombs L, Preece A, Kelleher D. Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study. Int J Chron Obstruct Pulmon Dis. 2015;10:15–23. doi:10.2147/COPD.S6809425565796
   PubMed Web of Science ®Google Scholar
• Mehta R, Hardes K, Kelleher D, Preece A, Tombs L, Brealey N. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study. Clin Ther. 2014;36(7):1016–1027 e1012. doi:10.1016/j.clinthera.2014.05.00224947493
   PubMed Web of Science ®Google Scholar
• Mehta R, Kelleher D, Preece A, Hughes S, Crater G. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. Int J Chron Obstruct Pulmon Dis. 2013;8:159–167. doi:10.2147/COPD.S4085923569370
   PubMed Web of Science ®Google Scholar
• Kelleher D, Tombs L, Preece A, Brealey N, Mehta R. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Pulm Pharmacol Ther. 2014;29(1):49–57. doi:10.1016/j.pupt.2014.07.00225020273
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H. A systematic review of the efficacy and safety of a fixed-dose combination of umeclidinium and vilanterol for the treatment of COPD. Chest. 2015;148(2):397–407. doi:10.1378/chest.15-008425798635
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ora J, Matera MG, Cazzola M, Calzetta L. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opin Drug Saf. 2018;17(6):589–596. doi:10.1080/14740338.2018.147223229716427
   PubMed Web of Science ®Google Scholar
• Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis. 2013;7(6):311–319. doi:10.1177/175346581349978924004659
   PubMed Web of Science ®Google Scholar
• Malerba M, Morjaria JB, Radaeli A. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD–role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2014;9:687–695. doi:10.2147/COPD.S4779225061288
   PubMed Web of Science ®Google Scholar
• Albertson TE, Harper R, Murin S, Sandrock C. Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol. Patient Prefer Adherence. 2015;9:235–242. doi:10.2147/PPA.S7153525673975
   PubMed Web of Science ®Google Scholar
• Ray R, Tombs L, Asmus MJ, et al. Efficacy of Umeclidinium/Vilanterol in elderly patients with COPD: a pooled analysis of randomized controlled trials. Drugs Aging. 2018;35(7):637–647. doi:10.1007/s40266-018-0558-y29951734
   PubMed Web of Science ®Google Scholar
• Donohue JF, Niewoehner D, Brooks J, O’Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15:78. doi:10.1186/1465-9921-15-7825015176
   PubMed Web of Science ®Google Scholar
• Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486. doi:10.1016/S2213-2600(14)70065-724835833
   PubMed Web of Science ®Google Scholar
• Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8(6):169–181. doi:10.1177/175346581455920925452426
   PubMed Web of Science ®Google Scholar
• F.D.A. U.S. Food and Drug Administration. 2018 Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203975. Accessed November 29, 2018.
   Google Scholar
• Siler TM, Donald AC, O’Dell D, Church A, Fahy WA. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62. 5/25mug on health-related quality of life in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:971–979. doi:10.2147/COPD.S10296227274218
   PubMed Web of Science ®Google Scholar
• Riley JH, Kalberg CJ, Donald A, Lipson DA, Shoaib M, Tombs L. Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study. ERJ Open Res. 2018;4(1):00073–2017. doi:10.1183/23120541.00073-201729322050
   PubMedGoogle Scholar
• Zheng J, Zhong N, Newlands A, Church A, Goh AH. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis. 2015;10:1753–1767. doi:10.2147/COPD.S8105326366068
   PubMed Web of Science ®Google Scholar
• Donohue JF, Singh D, Munzu C, Kilbride S, Church A. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials. Respir Med. 2016;112:65–74. doi:10.1016/j.rmed.2016.01.00126797016
   PubMed Web of Science ®Google Scholar
• Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870–881. doi:10.1016/j.rmed.2015.04.01826006754
   PubMed Web of Science ®Google Scholar
• Kalberg C, O’Dell D, Galkin D, Newlands A, Fahy WA. Dual bronchodilator therapy with Umeclidinium/Vilanterol versus tiotropium plus indacaterol in chronic obstructive pulmonary disease: a randomized controlled trial. Drugs R D. 2016;16(2):217–227. doi:10.1007/s40268-016-0131-227028749
   PubMedGoogle Scholar
• Kerwin E, Ferguson GT, Sanjar S, et al. Dual bronchodilation with indacaterol Maleate/Glycopyrronium bromide compared with umeclidinium bromide/vilanterol in patients with moderate-to-severe COPD: results from two randomized, controlled, cross-over studies. Lung. 2017;195(6):739–747. doi:10.1007/s00408-017-0055-928993871
   PubMed Web of Science ®Google Scholar
• Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34(11):2518–2533. doi:10.1007/s12325-017-0626-429094315
   PubMed Web of Science ®Google Scholar
• Alcázar Navarrete B, Boucot I, Naya I, et al. Umeclidinium/Vilanterol versus Tiotropium/Olodaterol in maintenance-naïve patients with moderate symptomatic chronic obstructive pulmonary disease: a post hock analysis. Pulm Ther. 2018;4:171–183. doi.org/10.1007/s41030-018-0057-7.
   Google Scholar
• Hahn B, Hull M, Blauer-Peterson C, Buikema AR, Ray R, Stanford RH. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA. Respir Med. 2018;139:65–71. doi:10.1016/j.rmed.2018.04.01429858004
   PubMed Web of Science ®Google Scholar
• Buikema AR, Brekke L, Anderson A, et al. The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models. Multidiscip Respir Med. 2018;13:38. doi:10.1186/s40248-018-0151-630338068
   PubMed Web of Science ®Google Scholar
• Chapin TW, Mann MA, Brown GL, Leitheiser TL, Anderson B, Leedahl DD. Effectiveness of umeclidinium-vilanterol for protocolized management of chronic obstructive pulmonary disease exacerbation in hospitalized patients: a sequential period analysis. Chronic Obstr Pulm Dis. 2018;5(1):38–45. doi:10.15326/jcopdf.5.1.2017.016329629403
   PubMed Web of Science ®Google Scholar
• Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017;12:997–1008. doi:10.2147/COPD.S12442028392684
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• Pascoe SJ, Lipson DA, Locantore N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48(2):320–330. doi:10.1183/13993003.02165-201527418551
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
   PubMed Web of Science ®Google Scholar
• Aziz MIA, Tan LE, Wu DB, et al. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3203–3231. doi:10.2147/COPD.S17347230349228
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Strange C. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? Int J Chron Obstruct Pulmon Dis. 2018;13:2587–2601. doi:10.2147/COPD.S17224030214177
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018;52:1801219. doi:10.1183/13993003.01219-201830190269
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(3):CD010115. doi:10.1002/146518558.CD010115.pub2.
   Web of Science ®Google Scholar
• Ye W, Guo X, Yang T, Han F. Systematic review of inhaled corticosteroid withdrawal effects in chronic obstructive pulmonary disease, and comparison with two “real-life” studies. J Thorac Dis. 2018;10(7):4565–4573. doi:10.21037/jtd.2018.06.15130174909
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, Matera MG. Triple therapy versus single and dual long-acting bronchodilator therapy in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Eur Respir J. 2018;52:1801586. doi:10.1183/13993003.01586-201830309975
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335–371. doi:10.1378/chest.127.1.33515654001
   PubMed Web of Science ®Google Scholar
• Ninane V, Vandevoorde J, Cataldo D, et al. New developments in inhaler devices within pharmaceutical companies: a systematic review of the impact on clinical outcomes and patient preferences. Respir Med. 2015;109(11):1430–1438. doi:10.1016/j.rmed.2015.09.01326439177
   PubMed Web of Science ®Google Scholar
• Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013;13:72. doi:10.1186/1471-2466-13-7224314123
   PubMed Web of Science ®Google Scholar
• van der Palen J, Moeskops-van Beurden W, Dawson CM, et al. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2515–2523. doi:10.2147/COPD.S16906030174421
   PubMed Web of Science ®Google Scholar
• Collison KA, Patel P, Preece AF, Stanford RH, Sharma RK, Feldman G. A randomized clinical trial comparing the ELLIPTA and handihaler dry powder inhalers in patients with COPD: inhaler-specific attributes and overall patient preference. Copd. 2018;15(1):46–50. doi:10.1080/15412555.2017.140000029227727
   PubMedGoogle Scholar
• Kocks JWH, Chrystyn H, van der Palen J, et al. Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD. NPJ Prim Care Respir Med. 2018;28(1):43. doi:10.1038/s41533-018-0110-x30446655
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62. 5/25mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752–1760. doi:10.1016/j.rmed.2014.10.00225458157
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Kalberg CJ, Galkin DV, et al. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study. Int J Chron Obstruct Pulmon Dis. 2017;12:745–755. doi:10.2147/COPD.S11903228280319
   PubMed Web of Science ®Google Scholar